LT 3001

Drug Profile

LT 3001

Alternative Names: LT3001

Latest Information Update: 01 Dec 2015

Price : $50

At a glance

  • Originator Lumosa Therapeutics
  • Class Antithrombotics; Neuroprotectants; Peptides; Small molecules
  • Mechanism of Action Antioxidants; Free radical scavengers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Stroke

Most Recent Events

  • 01 Dec 2015 LT 3001 is available for licensing as of 01 Dec 2015.
  • 30 Nov 2015 Preclinical trials in Stroke in Taiwan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top